STIM1 Trial: Update of the Stop Imatinib Study in CML


STIM1 Trial: Update of the Stop Imatinib Study in CML
Slides from a presentation at ASH 2015 and transcribed comments from a recent interview with Richard M Stone, MD (2/16/16)

Etienne G et al. Long-term follow-up of the French 1 Stop Imatinib study (STIM1) in chronic myeloid leukemia patients. Proc ASH 2015;Abstract 345.

Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.